Suven has been 50% owned by Advent since 2022 acquisition, with the remaining with public and institutional shareholders while Cohance is wholly owned by the PE group. Now post merger, Advent will own 66.7% in the combined entity and the public shareholders the rest.
Advent International on Monday said it has entered into a definitive agreement to acquire a significant stake in Suven Pharmaceuticals from the Jasti family, subject to regulatory approvals and conditions
Advent International, one of the largest and most experienced global PE investors, has entered into a definitive agreement to acquire significant stake in Suven Pharmaceuticals from the Jasti family, subject to regulatory approvals and conditions.
Mumbai, Dec 26: Global private equity investor Advent International on Monday said it is acquiring a significant stake in Suven Pharmaceuticals from its promoters, the Jasti family. The PE major said this will be followed with an open offer to acquire 26 per cent more in the listed contract development and manufacturing organisation from public shareholders, and also merge the company with investee company Cohance Lifesciences, as per an official statement. Media reports on a Monday morning pegged the acquisition […]